Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Type:
Grant
Filed:
January 7, 2016
Date of Patent:
December 27, 2016
Assignee:
TEL-AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P.
Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Type:
Application
Filed:
January 7, 2016
Publication date:
April 28, 2016
Applicant:
Tel-Aviv University Future Technology Development L.P.
Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
February 16, 2016
Assignee:
TEL-AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P.
Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.
Type:
Grant
Filed:
August 26, 2013
Date of Patent:
March 31, 2015
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.
Type:
Grant
Filed:
June 6, 2010
Date of Patent:
November 18, 2014
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.
Type:
Grant
Filed:
October 17, 2013
Date of Patent:
October 21, 2014
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X—Y or Y—X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.
Type:
Grant
Filed:
December 22, 2009
Date of Patent:
April 15, 2014
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.
Type:
Grant
Filed:
February 13, 2012
Date of Patent:
April 8, 2014
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.
Type:
Application
Filed:
October 17, 2013
Publication date:
February 13, 2014
Applicant:
TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P.
Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.
Type:
Application
Filed:
August 26, 2013
Publication date:
December 19, 2013
Applicant:
Tel Aviv University Future Technology Development L.P.
Abstract: A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.
Type:
Grant
Filed:
April 9, 2009
Date of Patent:
October 22, 2013
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.
Type:
Grant
Filed:
March 14, 2012
Date of Patent:
August 6, 2013
Assignee:
Tel-Aviv University Future Technology Development L.P.
Inventors:
Rimona Margalit, Noga Yerushalmi, Dan Peer, Ilia Rivkin
Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Type:
Application
Filed:
September 27, 2012
Publication date:
April 18, 2013
Applicant:
TEL-AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P.
Abstract: Compounds having one or more phenol moieties, derivatives thereof, compositions containing same and uses thereof for the treatment of amyloid-associated diseases are provided.
Type:
Application
Filed:
November 27, 2012
Publication date:
March 28, 2013
Applicant:
Tel Aviv University Future Technology Development L.P.
Inventor:
Tel Aviv University Future Technology Development
Abstract: Compounds having one or more phenol moieties, derivatives thereof, compositions containing same and uses thereof for the treatment of amyloid-associated diseases are provided.
Type:
Grant
Filed:
March 23, 2006
Date of Patent:
February 12, 2013
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
October 2, 2012
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.
Type:
Application
Filed:
March 14, 2012
Publication date:
July 5, 2012
Applicant:
Tel-Aviv University Future Technology Development L.P.
Inventors:
Rimona MARGALIT, Noga Yerushalmi, Dan Peer, Ilia Rivkin
Abstract: A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.
Type:
Application
Filed:
February 13, 2012
Publication date:
June 14, 2012
Applicant:
Tel Aviv University Future Technology Development L.P.
Abstract: An electrical energy storage device (20,70) includes a substrate (22), which is formed so as to define a multiplicity of micro-containers separated by electrically-insulating and ion-conducting walls (32). A first plurality of anodes (A) is disposed in a first subset (24) of the micro-containers, and a second plurality of cathodes (C) is disposed in a second subset (26) of the micro-containers. The anodes and cathodes are arranged in an interlaced pattern.
Type:
Grant
Filed:
April 20, 2005
Date of Patent:
May 29, 2012
Assignee:
Tel Aviv University Future Technology Development L.P.
Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.
Type:
Grant
Filed:
November 2, 2005
Date of Patent:
May 15, 2012
Assignee:
Tel-Aviv University Future Technology Development L.P.
Inventors:
Rimona Margalit, Noga Yerushalmi, Dan Peer, Ilia Rivkin